Stock Events

Stock Events

Korro Bio 

$12.24
72
+$0.62+5.34% Friday 20:00
+$0.00+0%Friday 20:01After hours

Statistics

Day High
12.27
Day Low
12.2
52W High
55.89
52W Low
5.2
Volume
9,707
Avg. Volume
-
Mkt Cap
180.24M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-2.74
-2.18
-1.63
-1.07
Expected EPS
-1.26106
Actual EPS
N/A

Financials

-1,834.48%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
6.39MRevenue
-117.26MNet Income

Analyst Ratings

20.25Average Price Target
The highest estimate is 23.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KRRO. It's not an investment recommendation.
NVIDIA
7
NVDA
Apple
6
AAPL
Microsoft
6
MSFT
Alphabet
6
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Beam Therapeutics
BEAM
Mkt Cap3.03B
Beam Therapeutics uses base editing technology, similar to Korro Bio's RNA editing, for precise genetic modifications.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine is involved in genome editing using CRISPR technology, competing in the broader genetic modification space.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is a leader in CRISPR-Cas9 technology for gene editing, directly competing in the genetic therapy market.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics focuses on CRISPR-Cas9 for gene editing, similar to Korro Bio's focus on precise genetic modifications.
Precision Biosciences
DTIL
Mkt Cap214.74M
Precision BioSciences utilizes its ARCUS genome editing platform, offering a different approach but competing in the same space as Korro Bio.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, which, while a different technology, competes in the RNA-based therapy market.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, competing in the RNA therapy space.
Novartis
NVS
Mkt Cap292.35B
Novartis has a broad portfolio including gene therapies and investments in genetic editing technologies, making it a competitor on multiple fronts.

About

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Show more...
CEO
Ram Aiyar
Employees
57
Country
United States
ISIN
US5009461089

Listings

XNAS
US
KRRO
BOATS
BOATS
KRRO.BOATS

0 Comments

Share your thoughts

FAQ

What is Korro Bio stock price today?▼
The current price of KRRO is $12.24 USD — it has increased by +5.34% in the past 24 hours. Watch Korro Bio stock price performance more closely on the chart.
What is Korro Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Korro Bio stocks are traded under the ticker KRRO.
Is Korro Bio stock price growing?▼
KRRO stock has fallen by -5.19% compared to the previous week, the month change is a +6.43% rise, over the last year Korro Bio has showed a -63.11% decrease.
What is Korro Bio market cap?▼
Today Korro Bio has the market capitalization of 180.24M
When is the next Korro Bio earnings date?▼
Korro Bio is going to release the next earnings report on November 18, 2026.
What were Korro Bio earnings last quarter?▼
KRRO earnings for the last quarter are -1.07 USD per share, whereas the estimation was -1.34 USD resulting in a +20.03% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Korro Bio revenue for the last year?▼
Korro Bio revenue for the last year amounts to 6.39M USD.
What is Korro Bio net income for the last year?▼
KRRO net income for the last year is -117.26M USD.
How many employees does Korro Bio have?▼
As of September 05, 2026, the company has 57 employees.
In which sector is Korro Bio located?▼
Korro Bio operates in the Health & Wellness sector.
When did Korro Bio complete a stock split?▼
The last stock split for Korro Bio was on November 06, 2023 with a ratio of 1:50.
Where is Korro Bio headquartered?▼
Korro Bio is headquartered in CAMBRIDGE, United States.